MEMPHASYS LTD (F:IG7) — Market Cap & Net Worth
Market Cap & Net Worth: MEMPHASYS LTD (IG7)
MEMPHASYS LTD (F:IG7) has a market capitalization of $4.27 Million (€3.65 Million) as of May 22, 2026. Listed on the F stock exchange, this Germany-based company holds position #28797 globally and #2505 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MEMPHASYS LTD's stock price €0.00 by its total outstanding shares 2847233743 (2.85 Billion). Review MEMPHASYS LTD balance sheet liabilities to assess the company's total debt and financial obligations.
MEMPHASYS LTD Market Cap History: 2019 to 2026
MEMPHASYS LTD's market capitalization history from 2019 to 2026. Data shows change from $96.53 Million to $4.99 Million (-23.02% CAGR).
MEMPHASYS LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MEMPHASYS LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
249.65x
MEMPHASYS LTD's market cap is 249.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $23.30 Million | $27.15K | -$2.08 Million | 858.30x | N/A |
| 2023 | $11.65 Million | $15.37K | -$3.40 Million | 757.95x | N/A |
| 2024 | $14.98 Million | $60.00K | -$4.44 Million | 249.65x | N/A |
Competitor Companies of IG7 by Market Capitalization
Companies near MEMPHASYS LTD in the global market cap rankings as of May 22, 2026.
Key companies related to MEMPHASYS LTD by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #151 globally with a market cap of $152.62 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #198 globally with a market cap of $119.97 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #257 globally with a market cap of $97.77 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #151 | Abbott Laboratories | NYSE:ABT | $152.62 Billion | $87.77 |
| #198 | Stryker Corporation | NYSE:SYK | $119.97 Billion | $313.50 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #257 | Medtronic PLC | NYSE:MDT | $97.77 Billion | $78.15 |
MEMPHASYS LTD Historical Marketcap From 2019 to 2026
Between 2019 and today, MEMPHASYS LTD's market cap moved from $96.53 Million to $ 4.99 Million, with a yearly change of -23.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.99 Million | -57.14% |
| 2025 | €11.65 Million | -22.22% |
| 2024 | €14.98 Million | +28.57% |
| 2023 | €11.65 Million | -50.00% |
| 2022 | €23.30 Million | -87.72% |
| 2021 | €189.74 Million | -3.39% |
| 2020 | €196.39 Million | +103.45% |
| 2019 | €96.53 Million | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of MEMPHASYS LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.27 Million USD |
| MoneyControl | $4.27 Million USD |
| MarketWatch | $4.27 Million USD |
| marketcap.company | $4.27 Million USD |
| Reuters | $4.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more